

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF VIRGINIA  
Norfolk Division**

BIONTECH SE, BIONTECH	)	
MANUFACTURING GMBH, and	)	
PFIZER INC.,	)	
	)	
Plaintiffs/Counterclaim Defendants,	)	C.A. No. 2:23cv222-JKW-DEM
	)	
v.	)	
	)	JURY TRIAL DEMAND
CUREVAC SE (f/k/a CUREVAC AG),	)	
	)	
	)	
Defendant/Counterclaimant,	)	
	)	
and	)	
	)	
CUREVAC MANUFACTURING GMBH,	)	
	)	
Counterclaimant.	)	

**JOINT SUPPLEMENTAL BRIEF ON THE MOTION TO REDUCE  
THE NUMBER OF ASSERTED CLAIMS**

Plaintiffs and Counterclaim Defendants, BioNTech SE, BioNTech Manufacturing GmbH, and Pfizer Inc. (collectively, “Plaintiffs”), and Defendant and Counterclaim Plaintiff CureVac SE (f/k/a CureVac AG) and Counterclaim Plaintiff CureVac Manufacturing GmbH, (collectively “CureVac”), by counsel, in response to the Court’s Order of May 31, 2024 (ECF No. 305), submit this Joint Supplemental Brief on the Motion to Reduce the Number of Asserted Claims (ECF No. 254):

1. On June 5, 2024, in response to the Court’s Order of May 31, 2024 (ECF No. 305), the Parties exchanged proposals to resolve the disagreements concerning the process to reduce the number of asserted claims and to thereby resolve the Motion to Reduce the Number of Asserted Claims (ECF No. 254).

2. On June 6, 2024, the Parties met and conferred to discuss the Parties' respective proposals in an effort to reach agreement.

3. The Parties thereafter resolved their disagreement concerning the process to reduce the number of asserted claims, and therefore the Motion to Reduce the Number of Asserted Claims, as follows:

- (a) CureVac will reduce the number of claims asserted to no more than 50 (from among the 68 claims currently identified) on or before June 25, 2024; and
- (b) CureVac will reduce the number of claims asserted to no more than 20 (from among the 50 claims identified on June 25, 2024) within 14 days after the close of expert discovery.

Dated: June 11, 2024

/s/ Stephen E. Noona

Stephen E. Noona (VSB No. 25367)  
KAUFMAN & CANOLES, P.C.  
150 W. Main Street, Suite 2100  
Norfolk, VA 23510-1665  
Telephone: (757) 624-3239  
Facsimile: (888) 360-9092  
senoona@kaufcan.com

*Counsel for Plaintiffs BioNTech and Pfizer*

Bruce M. Wexler (*pro hac vice*)  
Eric W. Dittmann (*pro hac vice*)  
Young J. Park (*pro hac vice*)  
Mi Zhou (*pro hac vice*)  
Max H. Yusem (*pro hac vice*)  
Michael F. Werno (*pro hac vice*)  
PAUL HASTINGS LLP  
200 Park Avenue  
New York, NY 10166  
Telephone: (212) 318-6000  
Facsimile: (212) 319-4090  
michaelwerno@paulhastings.com

/s/ John M. Erbach

Dana D. McDaniel (VSB No. 25419)  
John M. Erbach (VSB No. 76695)  
M. F. Connell Mullins, Jr. (VSB No. 47213)  
Chris Bascom (VSB No. 87302)  
Clay S. Hester (VSB No. 93051)  
SPOTTS FAIN P.C.  
411 E. Franklin St., Suite 600  
Richmond, VA 23219  
T: (804) 297-2000  
F: (804) 697-2144  
E: dmcdaniel@spottsfain.com  
jerbach@spottsfain.com  
cmullins@spottsfain.com  
cbascom@spottsfain.com  
chester@spottsfain.com

Mark H. Izraelewicz (admitted *pro hac vice*)  
Kevin M. Flowers, Ph.D. (admitted *pro hac vice*)  
John R. Labbe (admitted *pro hac vice*)  
Michael R. Weiner (admitted *pro hac vice*)  
Sandip H. Patel (admitted *pro hac vice*)

ericdittmann@paulhastings.com  
youngpark@paulhastings.com  
mizhou@paulhastings.com  
maxyusem@paulhastings.com  
michaelwerno@paulhastings.com

*Counsel for Plaintiffs BioNTech SE and  
BioNTech Manufacturing GmbH*

Dimitrios T. Drivas (*pro hac vice*)  
John P. Scheibeler (*pro hac vice*)  
Kevin J. Georgek (*pro hac vice*)  
Samantha J. Kokonis (*pro hac vice*)  
WHITE & CASE LLP  
1221 Avenue of the Americas  
New York, NY 10020  
Telephone (212) 819-8200  
Facsimile: (212) 354-8113  
ddrivas@whitecase.com  
jscheibeler@whitecase.com  
kevin.georgek@whitecase.com  
samantha.kokonis@whitecase.com

*Counsel for Plaintiff Pfizer Inc.*

Michael J. Allikian (admitted *pro hac vice*)  
Thomas R. Burns (admitted *pro hac vice*)  
Chelsea M. Murray (admitted *pro hac vice*)  
Daniel Gonzalez (admitted *pro hac vice*)  
Izabella N. C. Higson (admitted *pro hac vice*)  
MARSHALL GERSTEIN & BORUN LLP  
233 S. Wacker Dr., Suite 6300  
Chicago, Illinois 60606  
T: 312.474.6300  
E: mizraelewicz@marshallip.com  
kflowers@marshallip.com  
jlabbe@marshallip.com  
mweiner@marshallip.com  
spatel@marshallip.com  
mallikian@marshallip.com  
tburns@marshallip.com  
cmurray@marshallip.com  
ihigson@marshallip.com  
dgonzalez@marshallip.com

*Counsel for Defendant-Counterclaimants  
CureVac SE and CureVac Manufacturing  
GmbH*